181 related articles for article (PubMed ID: 17888078)
21. Electroencephalographic and Electrocardiographic Effect of Intravenous Lacosamide in Refractory Focal Epilepsy.
Huang CW; Brown S; Pillay N; Campo MD; Tellez-Zenteno J; McLachlan RS
J Clin Neurophysiol; 2018 Sep; 35(5):365-369. PubMed ID: 29851686
[TBL] [Abstract][Full Text] [Related]
22. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.
Harris JA; Murphy JA
Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834
[TBL] [Abstract][Full Text] [Related]
23. Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures.
Rudd GD; Haverkamp W; Mason JW; Wenger T; Jay G; Hebert D; Doty P; Horstmann R
Acta Neurol Scand; 2015 Nov; 132(5):355-63. PubMed ID: 25933358
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial.
Ferreira JA; Le Pichon JB; Abdelmoity AT; Dilley D; Dedeken P; Daniels T; Byrnes W
Seizure; 2019 Oct; 71():166-173. PubMed ID: 31374487
[TBL] [Abstract][Full Text] [Related]
25. Lacosamide add-on therapy for partial epilepsy.
Weston J; Shukralla A; McKay AJ; Marson AG
Cochrane Database Syst Rev; 2015 Jun; (6):CD008841. PubMed ID: 26077821
[TBL] [Abstract][Full Text] [Related]
26. Lacosamide: in partial-onset seizures.
Cross SA; Curran MP
Drugs; 2009; 69(4):449-59. PubMed ID: 19323588
[TBL] [Abstract][Full Text] [Related]
27. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers.
Kropeit D; Johnson M; Cawello W; Rudd GD; Horstmann R
Acta Neurol Scand; 2015 Nov; 132(5):346-54. PubMed ID: 25932544
[TBL] [Abstract][Full Text] [Related]
28. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
29. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature.
Simoens S
Curr Med Res Opin; 2011 Jul; 27(7):1329-38. PubMed ID: 21561394
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.
Makedonska I; Ng YT; Beller C; Bozorg A; Csikós J; McClung C; Moeltgen H; Farkas MK;
Ann Clin Transl Neurol; 2024 Mar; 11(3):768-779. PubMed ID: 38375995
[TBL] [Abstract][Full Text] [Related]
31. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
32. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
Wymer JP; Simpson J; Sen D; Bongardt S;
Clin J Pain; 2009 Jun; 25(5):376-85. PubMed ID: 19454870
[TBL] [Abstract][Full Text] [Related]
34. [The efficacy of intravenous lacosamide in psychiatric hospital].
Vakula IN; Bojko EO; Vorona UA; Storozhuk JA; Nikiforova EU; Nikiforova DI; Glazunova TI
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2):67-70. PubMed ID: 27029451
[TBL] [Abstract][Full Text] [Related]
35. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
36. BGG492 as an adjunctive treatment in patients with partial-onset seizures: A 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension.
Elger CE; Hong SB; Brandt C; Mancione L; Han J; Strohmaier C
Epilepsia; 2017 Jul; 58(7):1217-1226. PubMed ID: 28500678
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.
Zadeh WW; Escartin A; Byrnes W; Tennigkeit F; Borghs S; Li T; Dedeken P; De Backer M;
Seizure; 2015 Sep; 31():72-9. PubMed ID: 26362380
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of a new antiepileptic drug lacosamide in patients with focal epilepsy: data of double-blind placebo controlled trials].
Mil'chakova LE; Gekht AB
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3 Suppl 2):39-43. PubMed ID: 20873472
[No Abstract] [Full Text] [Related]
39. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy.
Pasha I; Kamate M; Didagi SK
Pediatr Neurol; 2014 Oct; 51(4):509-14. PubMed ID: 25266613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
